Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBD-IL-12-expressing FAP CAR-T
- Development stage
- Preclinical
- Lead developer
- Jun Ishihara
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
CBD-IL-12-expressing FAP CAR-T is an engineered chimeric antigen receptor (CAR) T-cell therapy designed to target the fibrotic tumor microenvironment. It specifically targets fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts (CAFs). Upon binding to FAP, the CAR-T cells utilize NFAT signaling to trigger the localized secretion of interleukin-12 (IL-12) fused to a collagen-binding domain (CBD). This dual-action approach aims to deplete CAFs, thereby reducing the physical barrier to immune cell infiltration, while simultaneously concentrating IL-12 within the tumor stroma to enhance host immune activation. The CBD fusion minimizes systemic exposure and toxicity by ensuring the cytokine remains localized to the collagen-rich tumor matrix.
- Other names
- Collagen-binding IL-12-expressing FAP-CAR-T
02
Targets
FAP (Fibroblast activation protein alpha)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on CBD-IL-12-expressing FAP CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBD-IL-12-expressing FAP CAR-T.